Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-S2P-Targeted STAB2 Receptor PET Imaging in the Diagnosis of Large Artery Atherosclerosis
NCT07815860Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of 18F-S2P in large artery atherosclerosis (LAA), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Sensitivity of 18F-S2P PET/CT at 1 year. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
18F-S2P
03
Conditions
large artery atherosclerosis (LAA)
Beyond the preview
Go deeper on NCT07815860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815860.